ACM
FDMT icon

ADAR1 Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

ADAR1 Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-116,712
Closed -$1.09M – 303
2026
Q1 		$1.09M Hold
116,712
– – 0.06% 150
2025
Q4 		$875K Buy
116,712
+100,000
+598% +$1.01M 0.06% 141
2025
Q3 		$145K Buy
+16,712
New +$99.9K 0.01% 192
2024
Q4 		– Sell
-6,000
Closed -$64.9K – 247
2024
Q3 		$64.9K Buy
6,000
+4,000
+200% +$66.4K 0.01% 203
2024
Q2 		$42K Hold
2,000
– – 0.01% 195
2024
Q1 		$63.7K Buy
+2,000
New +$51K 0.01% 168

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

ADAR1 Capital Management's FDMT Position: Q2 2026 in Review

ADAR1 Capital Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 116,712 shares — an estimated $1.09M sold.

ADAR1 Capital Management first reported a position in FDMT in Q1 2024 and held it in 6 quarters. The position peaked at $1.09M in Q1 2026. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • ADAR1 Capital Management reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 116,712 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.09M.
  • ADAR1 Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 6 quarters.
  • ADAR1 Capital Management's 4D Molecular Therapeutics position peaked at $1.09M in Q1 2026.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.